ERYTHROPOIETIN TREATMENT FOR ANEMIA IN CHILDREN WITH CANCER – SINGLE CENTRE EXPERIENCES
Abstract
Background. Anemia, a common complication during treatment of malignant disease in children, was frequently treated with red blood cell transfusions. Several studies have shown, that the introduction of recombinant human erythropoietin (rh EPO) for treating anemia in patients has been effective in reducing the need for transfusions. Variable doses of EPO from 150 to 900 IU/kg body weight have been used usually three times weekly. Recently some studies showed equally effective once weekly administration of EPO with proposed doses for children of 450 to 600 IU/ kg body weight.
Efficacy and safety of once weekly EPO therapy was tested in 8/10 children treated in our Unit for solid tumors and nonHodgkin’s lymphoma. In this article we would like to present our one year experience with EPO treatment.
Patients and methods. Patients have subcutaneously received the EPO dose of 600 UI/ kg body weight once weekly. Hemoglobin response and transfusion needs before and during treatment with EPO were analyzed.
Results. Response was seen in 7/8 of patient, with increased hemoglobin level and lower transfusion needs. Only one patient was poor responder at first, but responded perfect after twice weekly EPO application. No adverse reaction related to EPO therapy was observed.
Conclusions. Our experience with treating anemia in pediatric cancer patients who undergo intensive and aggressive chemotherapy treatment regimens are good and promising. Once weekly dosage regimen is child friendly and acceptable way of treating anemia.
Downloads
References
Johnson R, Roodman G. Haematologic manifestations of malignancy. Dis Mon 1989; 35: 726–68.
Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966; 3: 351–1.
Duhrsen U, Hosseld DK. Hematopoietic growth factors and the treatment of tumor-associated anemias. Ann Hematol 1994; 69: 213–21.
Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Eng J Med 1990; 322: 1689–92.
Corrazza F, Beguin Y, Bergmann P et al. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythtropoietin production. Blood 1998; 92: 1793–98.
Skillings J, Sridhar F, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 1993; 16: 22–5.
Mohandas K, Aledort L. Transfusions requirements, risks and costs for patients with malignancy. Transfusion 1995; 35: 427–30.
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73–8.
Pincus T, Olsen NJ, Russel IJ et al. Multicenter study of recombinant human erythropoietin in correction of anemia in reumatoid arthritis. Am J Med 1990; 89: 161–68.
Klaesson S, Ringden O, Ljungman P, Lönnqiust B, Wennber L. Reduced blood transfusion requirements after allogeneic bone marrow transplantation: results of a randomized, double blind study with high-dose erythropoietin. Bone Marrow Transplant 1994; 13: 397–402.
Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized doubleblind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865–74.
Kasper C, Terhaar A, Fossa A, Welt A, Seeber S, Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur J Haematol 1997; 86: 251–6.
Cascinu S, Fredeli A, DelFerm E, Luzi Fedelli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin associated anaemia: a randomised double-blind trial with placebo. J Clin Oncol 1994; 12: 1058–62.
Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type. Results from a prospective community oncology study. Procrit Study Group. Clin Oncol 1998; 16: 3412–25.
Tsukada M, Moshimatsu I, Nagahara T et al. Clinical application of recombinant human erytropoietin for treatments in patients with head and neck cancer. Cancer Immunol Immunother 1993; 36: 52–6.
Lavey RS, Dempsei WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Phys1993; 27: 1147–52.
Shasha D. The negative impact of anemia on radiotherapy and chemoradiation outcomes. Sem Hematol 2001; 38: Suppl 7: 8–15.
Nenadov Beck M, Beck D. Recombinant erythropoietin in acute chemotherapy – induced anemia of children with cancer. Med Pediatr Oncol 1995; 25: 17–21.
Bolonaki I, Stiakaki E, Lydaki H, Dimitriou D, Kambourakis A, Kalmantis D, Kalmanti M. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 1996; 13: 111–21.
Varan A, Bűyűkpamukçu M, Kutluk T, Akyűz C. Recombinant human erythropoietin treatment for chemotherapy related anemia in children. Focus on Anaemia in cancer 2001; 2: 44–5.
Bűyűkpamukçu M, Varan, Kutluk T, Akyűz C. Is Epoetin Alfa a Treatment Option For Chemotherapy – Related Anemia in Children. Med Pediatr Oncol 2002; 39: 455–8.
Dunplay FR, Harrison BR, Dunleavy TL, Rodrignes JJ, Hilton JK, Boyd JH. Erythropoietin reduces anemia and transfusions. A randomized trial with or without erythropoietin during chemotherapy. Cancer 1999; 86: 1362–7.
Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhora LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients. Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875–82.
Cazzola M, Bequin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Hematol 2003; 122: 386–93.
Leon P, Jimenez M, Barona P, Sierrasesumaga L. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol 1998; 30: 110–16.
Porter JC, Leahey A, Polise K, Bunin G, Manno CS. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized double-blind, placebo-controlled trial. J Pediatr 1996; 129: 656–60.
McMahon PG, Vargas R, Ryan M et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76: 1718–22.
Zoubek A, Kronberger M. Early epoetin alfa treatment in children with solid tumors. Med Pediatr Oncol 2002; 39: 459–62.
Feusner J, Hastings C. Recombinant human erythropoietin in pediatric oncology: A review. Med Pediatr Oncol 2002; 39: 463–8.
Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, Kurz RW. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a doubleblind, randomized, Phase III study). Transfusion 1996; 36: 155–9.
Michon J. Incidence of anemia in pediatric cancer patients in Europe; Results of a large, international survey. Med Pediatr Oncol 2002; 39: 448–50.
Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994; 21: Suppl 3: 21–8.
Spivak JL. The biology and clinical applications of recombinant erythropoietin. Semin Oncol 1998; 25: Suppl 7: 7–11.
Maedougall JC, Cavill I, Hulme B et al. Detection of functional iron deficiency during erytropoietin treatment: a new approach. BMJ 1992; 304: 225–6.
Csaki C, Fenencz T, Schuler D, Borsi JD. Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumors. Eur J Cancer 1998; 34: 364–67.
Porter JC. Erythropoietin use in pediatric oncology. Transfusion Alternatives in Transfusion Medicine 2002; 4: 20–5.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
